Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bethanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bethanidine SCHEMBL34434 | 1.00 | ALOX12 (0.48) | ALOX12ALDH1A1HPGDMAPTGAA | |
| Bethanidine SCHEMBL34433 | 1.00 | ALOX12 (0.48) | ALOX12ALDH1A1HPGDMAPTGAA | |
| Bethanidine SCHEMBL11505129 | 0.98 | MAPT (0.50) | ALOX12ALDH1A1HPGDMAPTGAA | |
| Bethanidine SCHEMBL29390473 | 0.92 | KMT2A (0.43) | ALOX12ALDH1A1HPGDMAPTGAA | |
| Bethanidine SCHEMBL7530034 | 0.92 | KMT2A (0.43) | ALOX12ALDH1A1HPGDMAPTGAA | |
| Bethanidine SCHEMBL122035 | 0.92 | KMT2A (0.43) | ALOX12ALDH1A1HPGDMAPTGAA | |
| Bethanidine SCHEMBL122033 | 0.92 | KMT2A (0.43) | ALOX12ALDH1A1HPGDMAPTGAA | |
| SCHEMBL11840901 | 0.85 | ALOX12 (0.48) | ALOX12ALDH1A1HPGDMAPTGAA | |
| SCHEMBL11840897 | 0.85 | ALOX12 (0.48) | ALOX12ALDH1A1HPGDMAPTGAA | |
| Bethanidine SCHEMBL29285011 | 0.84 | MAOB (0.44) | ALOX12ALDH1A1HPGDMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230165836-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER | Université Catholique de Louvain (BE) | 2023-06-01 | — | — | US | claimed |
| US-20230149360-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS | Université Catholique de Louvain (BE) | 2023-05-18 | — | — | US | claimed |
| WO-2023055751-A1 | MIXED SOLVENT HYDROGEL SYSTEM FOR WOUND HEALING | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-04-06 | — | — | WO | claimed |
| EP-4138803-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER | Université catholique de Louvain (BE) | 2023-03-01 | — | — | EP | claimed |
| WO-1991012806-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | CAMPBELL JAMES N (US) | 1991-09-05 | — | — | WO | claimed |
| WO-1991009627-A1 | MEDICAMENT FOR TREATMENT OF HEART FAILURE | HEDNER THOMAS (SE) | 1991-07-11 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| US-4711887-A | HYPOTENSIVE AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-12-08 | — | — | US | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4238518-A | Process for the preparation of a stable Beta vulgaris extract | LABORATOIRE L. LAFON (FR) | 1980-12-09 | — | — | US | claimed |